CNS Relapse After HCT in FLT3-Mutated AML
Author Information
Author(s): Khouloud Kouidri, Fabian Acker, Rosa Toenges, Saskia Pfaff, Sarah Lindner, Julia Riemann, Marek Werth, Salem Ajib, Fabian Lang, Björn Steffen, Thomas Oellerich, Hubert Serve, Anjali Cremer, Gesine Bug
Primary Institution: Goethe University Frankfurt, University Hospital, Frankfurt, Germany
Hypothesis
What are the risk factors for CNS relapse in patients with FLT3-mutated AML after allogeneic hematopoietic cell transplantation?
Conclusion
Patients with FLT3-mutated AML and active disease at the time of HCT have a high risk of CNS relapse.
Supporting Evidence
- FLT3 mutations are present in nearly 30% of AML cases.
- CNS relapse in AML is rare but has a very high mortality rate.
- Patients without complete remission before HCT had a 50% cumulative incidence of CNS relapse at 2 years.
- Pre-emptive or salvage therapy with FLT3 inhibitors did not prevent CNS relapse.
- High white blood cell count and elevated LDH levels are risk factors for CNS involvement in AML.
Takeaway
This study found that patients with a specific type of leukemia had a high chance of their cancer coming back in the brain after treatment, especially if they weren't in remission before treatment.
Methodology
Retrospective analysis of clinical data from patients with FLT3-mutated AML who underwent HCT.
Potential Biases
Potential underestimation of CNS relapse due to lack of routine screening.
Limitations
The study is limited by its retrospective design and small sample size.
Participant Demographics
{"age":{"median":53,"range":"20-75"},"sex":{"male":22,"female":17}}
Statistical Information
P-Value
0.003
Confidence Interval
95% CI, 16–77
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website